Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CILO-PER
NCT02770274Phase 3Unknown
- Sponsor
- Attikon University Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cilostazol in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Attikon University Hospital. Primary endpoint: Composite endpoint of major adverse cardiovascular and limb events at 1 year. Status: unknown.
02
Drugs
cilostazol
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02770274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770274.